Inactive Instrument

News Pharmacyclics, Inc.

Equities

US7169331060

End-of-day quote Nasdaq Other stock markets
- ^USD	-

2015	Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal	RE
2015	Mylan NV : Exclusive - Perrigo expected to reject Mylan's latest offer	RE

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Pharmacyclics : Ibrutinib (IMBRUVICA®) Combination Data Show Promise in Patients with Relapsed/Refractory Multiple Myeloma	16-01-07	PU
Pharmacyclics : AbbVie’s Commitment to Oncology Demonstrated at the 57th American Society of Hematology Annual Meeting with 61 Abstracts Evaluating Medicines in Several Blood Cancers	16-01-07	PU
Pharmacyclics : IMBRUVICA® (ibrutinib) Awarded Prix Galien 2015 Best Pharmaceutical Agent	16-01-07	PU
Pharmacyclics : AbbVie Announces Submission of a Supplemental New Drug Application for IMBRUVICA® (ibrutinib) for Treatment–Naïve Chronic Lymphocytic Leukemia	16-01-07	PU
Pharmacyclics : IMBRUVICA® (ibrutinib) Now Approved to Treat Waldenström’s Macroglobulinemia in Europe	16-01-07	PU
Pharmacyclics : Ibrutinib (IMBRUVICA®) Improved Survival for Treatment–Naïve Chronic Lymphocytic Leukemia Patients in Phase III RESONATETM-2 Trial	16-01-07	PU
Pharmacyclics : Ibrutinib (IMBRUVICA®) Improved Survival for Treatment–Naïve Chronic Lymphocytic Leukemia Patients in Phase III RESONATE-2 Trial	16-01-07	PU
Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal	15-05-06	RE
Mylan NV : Exclusive - Perrigo expected to reject Mylan's latest offer	15-04-29	RE
Mylan NV : Generic drugmaker Teva makes $40 billion offer for rival Mylan	15-04-21	RE
Mylan NV : Exclusive - Perrigo expected to reject Mylan offer as soon as this week	15-04-21	RE
Pharmacyclics : Stock Updates on Biotech -- Celgene, Amgen, PDL BioPharma, Amarin, and Pharmacyclics	15-04-21	PR
Actavis : Generic drugmaker Mylan offers $29 billion for Perrigo	15-04-08	RE
Pharmacyclics : Solid Tumor Study Investigating Ibrutinib (IMBRUVICA®) in Combination with Anti-PD-L1 Antibody (MEDI4736) Commences in Patients with Relapsed/Refractory Non-Small Cell Lung, Breast and Pancreatic Cancers	15-04-01	PR
Pharmacyclics : Stockholders Encouraged to Contact Securities Law Firm about Takeover	15-03-10	PR
Pharmacyclics : Ryan & Maniskas, LLP : Announces Investigation of Pharmacyclics Inc.	15-03-09	PR
AbbVie : CEO defends Pharmacyclics deal to sceptical investors	15-03-05	RE
Wall Street closes up slightly ahead of jobs report	15-03-05	RE
AbbVie : CEO says new form of Humira could thwart generics	15-03-05	RE
AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	15-03-05	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Pharmacyclics, Inc.

Equities

US7169331060

Summary

Filters